Mission

To identify new trends and methodological challenges in oncology health economics and outcomes research with the intent of supporting education, awareness, and community engagement while working towards the development of recommendations to address them. 

Background

Oncology is one of the most rapidly evolving therapeutic areas with considerable clinical and economic burden. Health economics and outcomes research in oncology is complicated by (1) the diversity of the epidemiology and biology of various tumors, which limits the sample size and long-term follow-up in clinical trials, (2) the rapidly evolving treatment landscapes and variation in national management recommendations, and (3) the complexities of measuring costs and quality of life in patients and caregivers. Therefore, oncology health economics and outcomes research constitutes a unique segment, and our SIG aims to advance clinical and methodological knowledge for proper clinical and economic evaluation of oncology treatments and diagnostic tools.  

Goals

Engage the oncology community to raise awareness of key components in oncology HEOR and recommended practices.

Offer relevant and impactful educational presentations and activities on the latest oncology HEOR topics.

Create a space to support the discussion of methods of statistical analysis and economic evaluation in oncology, and approaches to support timely access of innovative oncology treatments and diagnostic tools.


Manuscript and Reports

  1. A Checklist for Ascertaining Study Cohorts in Oncology Health Services Research Using Secondary Data: Report of the ISPOR Oncology Good Outcomes Research Practices Working Group.
  2. Evaluating the role of single-arm trials in oncology decision-making: an interview with Sorrel Wolowacz, RTI Health Solutions

Webinars

  1. Measuring the Indirect Costs Driving Financial Toxicity in Oncology
  2. Assessing Causal Treatment Effect for Sequenced Oncology Regimens

Presentations

  1. ISPOR Europe 2023: An Effective Drug Is Not Enough: How Do We Improve Access to Molecular Testing to Enable Personalized Treatment in Oncology?
  2. ISPOR Europe 2022: Clinical Evidence for Health Technology Assessment in Oncology, Are We Going Backwards? Where Are We Going With Single-Arm Trials?

Leadership


Chair-Elect

Min-Hua Jen, PhD

Sr. Director, Eli Lilly
Uxbridge, LON, United Kingdom

Past Chair

Haitham Tuffaha, MSc, MBA, RPh, PhD, BSc

Health Technology Assessment Leader, University of Queensland, Centre for the Business and Economics of Health
Brisbane, QLD, Australia

Chair

Brittany Carson, PhD, MHEcon, BSc

Senior Medical Director, ApotheCom
New York, NY, United States

Working Groups

Member Engagement



Co-Chairs

Abeer Al Rabayah, MSc, MBA, BSc

Head, Center for Drug Policy & Technology Assessment, King Hussein Cancer Center
Amman, Jordan

Dem Aliaj, MSc

Health Economist & Equity, University of Lucerne
LU, LU, Switzerland

Swarnali Goswami

Manager, RWE, CHEORS
Chalfont, PA, United States

Marco Gross-Langenhoff

Associate Director HEOR, Astellas Pharma Europe Ltd
Unterhaching, BY, Germany

Sabina Nduaguba, MSc

Assistant Professor, West Virginia University
Morgantown, WV, United States

Shilpi Swami, MA

ConnectHEOR
London, LON, United Kingdom

Sorrel Wolowacz, PhD

Head, EU Health Economics, RTI Health Solutions
Manchester, United Kingdom

Lixia Yao, PhD

Associate Professor, Temple University
Chalfont, PA, United States

Questions or ideas? Please send an email to Oncologysig@ISPOR.org

Join this Special Interest Group

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×